MeSH tree: G05.728
Researchers have introduced a novel diagnostics method that can more sensitively detect gene fusions in B-cell acute lymphoblastic leukemia (B-ALL), the most common type of pediatric cancer, compared to other publicly available ...
May 14, 2026
0
5
Most prostate cancers rely on male sex hormones, known as androgens, to grow. As a result, standard treatment focuses on lowering androgen levels or blocking their activity, but many tumors eventually become resistant and ...
May 12, 2026
0
6
In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing ...
Mar 25, 2026
0
564
The first and largest dataset of genomic structure variations specific to childhood cancers was published today by scientists from St. Jude Children's Research Hospital and the National Cancer Institute. The researchers assembled ...
Mar 12, 2026
0
12
One of the biggest challenges in cancer treatment is chemoresistance: Tumors that initially respond well to chemotherapy become resistant over time. When that happens, treatment options are often limited.
Oct 30, 2025
0
39
What if a single test could simultaneously contribute to the diagnosis, characterization, and treatment guidance of childhood cancer—while helping avoid toxic or potentially unnecessary treatments?
Oct 24, 2025
0
12
In a new study published in the Journal of Hepatology, researchers from the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) show that only 15–20% of hepatocytes in newborn mice—dubbed clonogenic hepatocytes—are ...
Aug 28, 2025
0
14
Hospital for Sick Children in Toronto researchers are reporting that targeted RNA sequencing can detect clinically actionable alterations in 87% of tumors and provide decisive findings where DNA-seq either fails, returns ...
Scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have made one of the most important discoveries to date in the study and treatment of BRCA1-deficient cancers and drug resistance.
Jun 10, 2025
0
24
Research by UMass Chan Medical School scientists Sharon Cantor, Ph.D., and Jenna M. Whalen, Ph.D., poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.
Feb 25, 2025
0
20
